Holen Sie sich die Stockscreener-App
2.77
25.91%
0.57
Handel nachbörslich:
29.72
26.95
+972.92%
Schlusskurs vom Vortag:
$2.20
Offen:
$2.21
24-Stunden-Volumen:
22.61M
Relative Volume:
21.71
Marktkapitalisierung:
$91.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-0.8471
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+13.06%
1M Leistung:
+19.40%
6M Leistung:
+658.70%
1J Leistung:
-19.01%
1-Tages-Spanne:
$2.19
$2.81
1-Wochen-Bereich:
$2.15
$2.81
52-Wochen-Spanne:
$0.2404
$3.50
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Vergleichen Sie RLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.50 | 4.21B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.825 | 217.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2288 | 502.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.3695 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Can Relmada Therapeutics Inc. stock resist sector downturnsDollar Strength & Free Reliable Trade Execution Plans - newser.com
Will Relmada Therapeutics Inc. stock recover faster than marketJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Relmada Therapeutics Moves: Max Kates Joins Advisory Board - StocksToTrade
Relmada Therapeutics (RLMD) Advances Phase 3 Plans for Bladder C - GuruFocus
Relmada Therapeutics prices $100M securities offering - MSN
Relmada Therapeutics (RLMD) Launches $100 Million Stock and Warr - GuruFocus
Relmada Therapeutics stock falls after $100 million share offering By Investing.com - Investing.com UK
Relmada Therapeutics stock falls after $100 million share offering - Investing.com
Relmada Therapeutics prices $100 million stock offering at $2.20 per share - Investing.com
Relmada Therapeutics Receives FDA Feedback on NDV-01 Trials - TipRanks
Relmada’s NDV-01 shows 92% response rate in bladder cancer - Investing.com
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Relmada Therapeutics Announces 9-Month Follow-Up Safety and Efficacy Data for NDV-01 in Non-Muscle Invasive Bladder Cancer, with FDA Support for Future Registrational Trials - Quiver Quantitative
Relmada Therapeutics (NASDAQ: RLMD) prices 40,142,000-share offering for $100M - Stock Titan
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer - The Manila Times
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Why Relmada Therapeutics Inc. stock remains a top recommendationJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
What institutional flow reveals about Relmada Therapeutics Inc.Long Setup & Weekly Watchlist of Top Performers - newser.com
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - MarketBeat
What to expect from Relmada Therapeutics Inc. in the next 30 days - newser.com
Is Relmada Therapeutics Inc. building a consolidation baseJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com
Is Relmada Therapeutics Inc. stock ready for a breakoutEarnings Growth Summary & Fast Gain Stock Trading Tips - newser.com
Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com
Will breakout in Relmada Therapeutics Inc. lead to full recoveryNew Guidance & Community Trade Idea Sharing - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulation2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Will Relmada Therapeutics Inc. (4E2) stock beat revenue estimatesWall Street Watch & Stock Portfolio Risk Control - newser.com
Why Relmada Therapeutics Inc. stock attracts global investors2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
Will Relmada Therapeutics Inc. stock gain from lower inflationIndex Update & Low Risk High Reward Ideas - newser.com
Relmada Therapeutics (NASDAQ:RLMD) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
AdvisorShares Investments LLC Raises Stock Holdings in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics (RLMD) to Release Earnings on Thursday - MarketBeat
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):